Adjuvante Anwendung direkter Thrombininhibitoren bei Patienten mit fibrinolytischer Therapie des akuten Myokardinfarkts

The direct thrombin inhibitors hirudin and bivalirudin inhibit both fluid-phase and clot-bound thrombin. These agents have been extensively studied in clinical trials in comparison with intravenous unfractionated heparin (UFH), as adjuncts to fibrinolytic therapy for ST-elevation myocardial infarction (STEMI) and in percutaneous coronary intervention (PCI), and they are currently undergoing further evaluation in patients with non-ST elevation acute coronary syndromes (NSTEACS). In angiographic trials there were trends for patients treated with hirudin to be more likely to achieve Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow at 90 minutes than patients treated with UFH (65% versus 57% in TIMI-5; 41% versus 33% in Hirudin for the Improvement of Thrombolysis [HIT]-4; statistically nonsignificant differences in both trials). In Montréal Heart Institute trials and the multicenter Hirulog and Early Reperfusion or Occlusion (HERO)-1 trial the use of bivalirudin was associated with an increased incidence of TIMI grade 3 flow (85% versus 31%, p = 0.006; and 48% versus 35%, p = 0.02, respectively). These studies used streptokinase as the fibrinolytic agent except in TIMI-5 where alteplase was used. The initial clinical outcomes studies (Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes [GUSTO]-IIA and TIMI-9A) were discontinued early because of a high incidence of intracerebral bleeding (approximately 1.8%). Patients in these studies had either STEMI or NSTEACS, and thus not all were treated with fibrinolytic therapy. These studies were recommenced as GUSTO-IIB and TIMI-9B, using lower dosages of hirudin (0.1 mg/kg bolus + 0.1 mg/kg infusion for 96 hours). Neither TIMI-9B nor GUSTO-IIB showed an improvement in efficacy (death or reinfarction) or an increase in bleeding with hirudin. However, in the 1015 patients with STEMI treated with streptokinase in GUSTO-IIB, there was a 40% reduction in the combined incidence of death or myocardial infarction at 30 days (8.6% versus 14.4%, odds ratio [OR] 0.57, 95% confidence interval [CI] 0.38-0.87, p = 0.004). In the HERO-2 trial, 17073 patients receiving streptokinase for STEMI were randomized to receive either bivalirudin (0.25 mg/kg bolus and 0.5 mg/kg infusion for 12 hours followed by 0.25 mg/kg) or UFH (5000 IU bolus and 800-1000 IU/h infusion titrated to an activated partial thromboplastin time [APTT] of 50-75 seconds) for a total of 48 hours. Thirty-day mortality was similar in both groups (10.8% with bivalirudin versus 10.9% with UFH, OR 0.99, 95% CI 0.90-1.09, p = 0.85). There was a 30% reduction in the incidence of reinfarction before 96 hours (1.6% with bivalirudin versus 2.3% with UFH, OR 0.70, 95% CI 0.56-0.87, p = 0.001). Patients treated with bivalirudin had significantly more moderate bleeding (1.4% versus 1.1% with UFH, OR 1.32, 95% CI 1.0-1.74, p = 0.05). In a meta-analysis of patients with STEMI in the Direct Thrombin Inhibitor Trialists' collaboration, direct thrombin inhibitors were found to reduce the rate of reinfarction at 30 days (3.9% versus 4.8% with UFH, OR 0.80, 95% CI 0.71-0.90, p < 0.001), but did not reduce mortality (9.1% versus 9.0%, OR 1.02, 95% CI 0.94-1.11, p = 0.68) or the combined incidence of death/reinfarction at 30 days (11.8% versus 12.4%, OR 0.95, 95% CI 0.88-1.02, p = 0.18). There was no increase in major bleeding or intracerebral bleeding with direct thrombin inhibitor therapy. In conclusion, direct thrombin inhibitors reduce reinfarction, but not mortality, in patients with STEMI treated with fibrinolytic therapy. The major benefit of direct thrombin inhibitors appears to be in patients undergoing PCI, particularly after STEMI.

Abstract aus PubMed (NCBI) für den zitierten Eintrag, in der Originalsprache wiedergegeben. Maßgeblich ist die Fassung der Originalpublikation.

Das Abstract wird nicht übersetzt, damit die eigene Wortwahl der Autoren erhalten bleibt.

Der Überblick fasst Studien zu Hirudin und Bivalirudin versus unfraktioniertem Heparin als Begleittherapie der Fibrinolyse beim STEMI zusammen. In HERO-2 (17 073 Patienten) war die 30-Tage-Mortalität unter Bivalirudin und Heparin ähnlich (10,8 % vs. 10,9 %), Reinfarkte vor 96 h waren seltener (1,6 % vs. 2,3 %; OR 0,70; p = 0,001). Laut Metaanalyse senken direkte Thrombininhibitoren Reinfarkte (3,9 % vs. 4,8 %; p < 0,001), nicht aber die Mortalität; der größte Nutzen scheint bei PCI zu liegen.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Weitere begutachtete Studien in der Kategorie „Klinische Literatur“.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Auswirkungen der Hirudotherapie auf Leberfunktionen, Lipidprofil und Insulinsensitivität bei Ratten mit metabolischem Syndrom — Bilden A et al. (2026)
• Wirksamkeit und Sicherheit der Hirudotherapie zur Verbesserung der Spermienqualitätsparameter bei männlicher Infertilität: Eine randomisierte kontrollierte Studie — Abtahi-Forooshani M et al. (2026)
• Erfolgreiche Behandlung einer venösen Stauung eines retrograden Suralislappens mit Enoxaparin bei einem männlichen Patienten mit traumatischer Fußquetschverletzung: Ein Fallbericht — Velasco-Bustamante J et al. (2026)
• Untersuchung der therapeutischen Wirkungen der Behandlung mit medizinischen Blutegeln auf die Ischämie-Reperfusions-Schädigung der unteren Extremität — Ünal K et al. (2026)
• Wirksamkeit der Therapie mit medizinischen Blutegeln bei unterschiedlichen klinischen Anwendungen: Eine umfassende Studie aus Aserbaidschan — Farzali S et al. (2025)
• Hirudotherapie in der rekonstruktiven Chirurgie: Fallberichte und Übersicht — Heinz P et al. (2020)
• Hirudotherapie in der Wundheilung — Nair H et al. (2022)
• Hirudotherapie bei Extremitätenischämie auf der pädiatrischen Intensivstation: Eine retrospektive Beobachtungskohorte — Resch J et al. (2022)

Alle von der ASH analysierten Studien →